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Abstract
Purpose To review the mechanisms of sedative-hypnotic
action with respect to the risk of delirium imparted by
drugs that act on c-amino-butyric-acid type A receptors or
a2 adrenoceptors.
Source MEDLINE was searched for relevant articles.
Principal ﬁndings Development of the acute confusional
state of delirium is associated with longer intensive care
unit (ICU) and hospital lengths of stay, signiﬁcantly higher
risk of functional decline, and increased mortality. Dis-
ruption of sleep is a modiﬁable risk factor that may
contribute to delirium and cognitive dysfunction in ICU
patients. Among the functions of sleep are repair of
defective processes and restoration of the brain to a state
in which it is ready to acquire new knowledge. It is logical
that disruption of these processes may produce acute
confusion. Delirium develops through a complex interac-
tion between the patient’s baseline vulnerability (patient’s
predisposing risk factors before hospitalization) and pre-
cipitating factors or insults (modiﬁable events that occur
during hospitalization). The latter factors include both
sleep disruption and sedation. We present a hypothesis that
these two factors are causally linked through effects on
memory. Our hypothesis explains why patients randomized
to receive an a2 adrenoceptor agonist are less likely to
develop delirium (and the attendant cognitive dysfunction)
than those randomized to receive benzodiazepines.
Conclusion Herein we present our hypothesis that
alternate mechanisms of hypnotic action may differentiate
the deleriogenic properties of the two classes of sedatives.
Future studies should focus on whether a causal relation-
ship can be established between sedative administration,
sleep disruption, and delirium.
Re ´sume ´
Objectif Passer en revue les me ´canismes d’action
se ´datifs-hypnotiques par rapport au risque de delirium
imparti par les me ´dicaments qui agissent sur les re ´cepteurs
de l’acide c-amino-butyrique de type A (GABAA) et les
adre ´nocepteurs a2.
Source Une recherche a e ´te ´ effectue ´e dans la base de
donne ´es MEDLINE pour en extraire les articles pertinents.
Constatations principales L’apparition d’un e ´tat de
confusion aigu de delirium est associe ´ea ` des dure ´es
prolonge ´es de se ´jour a ` l’unite ´des soins intensifs (USI) et a `
l’ho ˆpital, a ` un risque signiﬁcativement plus e ´leve ´ de de ´clin
fonctionnel et a ` une mortalite ´ accrue. La perturbation du
sommeil est un facteur de risque modiﬁable qui pourrait
contribuer au delirium et a ` la dysfonction cognitive chez
les patients de l’USI. La re ´paration des processus
de ´ﬁcients et le re ´tablissement du cerveau a ` un e ´tat pre ´pare ´
a ` acque ´rir de nouvelles connaissances sont certaines des
fonctions du sommeil. Il est logique que la perturbation de
ces processus puisse provoquer une confusion aigue ¨.L e
delirium survient suite a ` une interaction complexe entre la
vulne ´rabilite ´ fondamentale du patient (les facteurs de
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delirium) et des facteurs ou le ´sions pre ´cipitants (e ´ve ´nements
modiﬁables survenant pendant l’hospitalisation). Ces
seconds facteurs comprennent les perturbations du sommeil
et la se ´dation. Nous pre ´sentons l’hypothe `se que ces deux
facteurs ont un lien de causalite ´ par le biais d’effets sur la
me ´moire. Notre hypothe `se explique pourquoi il est moins
probable que des patients randomise ´sa `recevoir un agoniste
de l’adre ´nocepteur a2 manifestent un delirium (et la
dysfonction cognitive concomitante) que des patients
randomise ´sa ` recevoir des benzodiaze ´pines.
Conclusion Nous pre ´sentons ici notre hypothe `se selon
laquelle des me ´canismes d’action hypnotique diffe ´rents
pourraient permettre de distinguer les proprie ´te ´s
de ´liroge `nes des deux classes de se ´datifs. Les e ´tudes
devraient a ` l’avenir essayer de de ´terminer s’il existe une
relation de causalite ´ entre l’administration de se ´datifs, les
perturbations du sommeil et le delirium.
Attainment of the lighter stage of general anesthesia is
practiced widely on intensive care patients to enable
patients to tolerate invasive diagnostic and therapeutic
(e.g., mechanical ventilation via an endotracheal tube)
maneuvers. These general anesthetics go on for days, if not
weeks, with escalating doses exposing the patient to
cumulative beneﬁts as well as to toxicities that are not
encountered in the few hours of anesthesia typical for
surgical patients in the operating room. The intensive care
unit (ICU) is the most expensive clinical environment by
far, consuming nearly 10% of all health care dollars in the
USA – nearly 1% of the total GDP! The focus of attempts
to curtail those costs has been on preventing complications
in order to reduce the ICU length of stay. Intensivists have
led this assault through widespread adoption of guidelines
that have resulted in decreases in catheter-associated
bloodstream infections, ventilator-associated pneumonias,
and stress-induced ulcers. They have launched ambitious
strategies to combat the ravages of sepsis with limited
success. However, little has been done to reduce the inci-
dence and prevalence of delirium, and the interplay
between sleep and sedative-hypnotics in the genesis of this
condition has not been explored. We ﬁrst present a review
of the restorative properties of sleep, particularly on cog-
nitive function, the clinical evidence for sleep disruption
and cognitive dysfunction in ICU patients, and how exist-
ing sedative-hypnotic agents may exacerbate or ameliorate
this situation. We performed a wide-ranging MEDLINE
search for relevant articles with keywords including
‘‘sleep’’, ‘‘sedation’’, ‘‘hypnotic’’, ‘‘delirium’’, ‘‘cognitive
dysfunction,’’ and ‘‘memory’’.
Sleep and restoration of cognitive function
Sleep is under control of two processes, a circadian clock
that regulates the appropriate timing of sleep and wakeful-
ness across the 24-hr day and a homeostatic process (‘‘sleep
homeostasis’’) that regulates sleep need and intensity
according to the time spent awake or asleep.
1 Sleep is a non-
homogenous state that can be divided into non-rapid eye
movement (NREM) sleep and rapid eye movement (REM;
‘‘paradoxical’’) sleep. Neurochemical changes accompany
thesedifferenttypesofsleep,withcholinergic(inbrainstem
and forebrain), noradrenergic (locus ceruleus), and seroto-
nergic (dorsal raphe) activity all becoming less active in
NREM sleep and cholinergic activity increasing in REM
sleep
2 (Fig. 1a). Activity in the ventrolateral pre-optic
nucleus (VLPO) is increased in NREM sleep, and the
c-aminobutyric acid (GABA)ergic/galanin input from
VLPO inhibits the histaminergic tuberomammillary
nucleus
3 (Fig. 1a). Orexinergic pathways from the perifor-
nical nucleus are inactive during NREM sleep (Fig. 1a).
3
Applying electroencephalogram (EEG) criteria, NREM
sleep is composed of four distinct stages. Stages 1 and 2
reﬂect light sleep and are followed by stages 3 and 4 of a
deep sleep plane. Stages 3 and 4 are often paired together as
slow-wave sleep (SWS), as the EEG in these stages is
dominated by a delta rhythm (frequency 0.5-4 Hz). Slow-
wave sleep may be the mechanism that drives sleep
homeostasis, as it peaks early on during sleep and decreases
with the decline in sleep pressure.
1 Physiologic repair of the
organism is accelerated during SWS, as evidenced by the
increase in the rate of anabolism.
4Within the brain, the slow
wave activity (the ‘‘power’’ in the delta rhythm range)
diminishes strengthening of synapses that have occurred
during wakefulness
5,6 and restores the brain to a state that is
subsequently capable of appropriately processing new sen-
sory input in the succeeding period of wakefulness.
7 These
synaptic homeostatic processes
6 accommodate the brain’s
energy
8 and space
9 requirements and allow the brain to
acquire new information,which wouldnotbepossiblein the
absence of downscaling synaptic strength.
The different forms of memory, referred to as declarative
or explicit (consciously accessible memories of fact-based
information – knowing ‘‘what’’) and non-declarative or
implicit (procedural memory – knowing ‘‘how’’) develop
over time through several unique stages (acquisition,
translocation, consolidation [comprising stabilization and
enhancement], and reconsolidation). Deeper stages of
NREM as well as REM sleep are required for some of these
stages of learning and memory.
2,10-12 Truncating stages of
sleepcanresultindevelopmentofcognitivedysfunction,
2,13
the most severe of which occurs following total sleep
deprivation.
10
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123We consider that impairment in the formation and
retrieval of memories may account for much of the cog-
nitive dysfunction associated with delirium. It seems
intuitive that memory deﬁcits combined with a ﬂuctuating
level of arousal (both symptoms of sleep deprivation) could
produce a disorientated patient with reduced attention
(Box) – a description of the delirious patient. Nonetheless,
sedative medication also directly affects memory (inde-
pendently from effects on sleep), and this likely also
contributes to the delirium phenotype.
Sleep disruption and cognitive dysfunction in ICU
patients
Early polysomnographic studies had revealed extreme
sleep disruption in ICU patients, with decreases in total
sleep time, altered sleep architecture (predominance of
stages 1 and 2 sleep, decreased or absent stages 3 and 4
and REM sleep, and shortened REM periods), sleep
Fig. 1 Neural mechanisms of c-aminobutyric acid (GABA)ergic and
a2 adrenoceptor agonist sedation. a Wakefulness is promoted by the
release of the arousal-promoting monoamine (red) neurotransmitters,
norepinephrine (NE), serotonin (5-HT), and histamine (His), from the
locus ceruleus (LC), dorsal raphe nucleus (DR), and tuberomamm-
illary nucleus (TMN), respectively, as well as acetylcholine (ACh;
orange) from the pedunculopontine and laterodorsal tegmental nuclei
(PPTg and LDTg) and orexin (OX; green) into the cortex, forebrain,
and subcortical areas. Conversely, during the deeper stages of NREM
sleep, the activity is reversed by the inhibitory action of GABA and
galanin (gal; purple) released from the ventrolateral pre-optic nucleus
(VLPO). b, c Activity in brain nuclei involved in sleep pathways under
sedation with a (b) GABAergic agent and c a2 adrenoceptor agonist.
Abbreviations: GABA gal = neurons containing GABA and galanin;
His = histamine; NA = noradrenergic; ORX = orexin; LC = locus
ceruleus; PeF = perifornical nucleus; TMN = tuberomammillary
nucleus; VLPO = ventrolateral pre-optic nucleus. Reproduced with
permission from Nelson et al. (a)
27 and modiﬁed with permission
(intensetimes issue 9; available at www.intensetimes.eu) from Sanders
et al.( b, c)
A
A Sanders RD, Hussell T, Maze M. Sedation & immunity: optimi-
sation for critically ill patients. Intense Times 2010; 9: 2-5
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123fragmentation,
14,15 and up to 50% of total sleep time
occurring during the light phase. Among the causes con-
tributing to sleep disruption in the ICU are those related to
the patient’s acute illness and co-morbidities, environ-
mental factors (including noise and inappropriate light),
and iatrogenic factors, including frequent care-related
interruptions and medications prescribed for analgesia and
sedation. Among the causes potentially amenable to mod-
iﬁcation, excessive noise appears not to contribute as much
as was anticipated,
16 and attention has focused on sedative
practices.
17,18 Several studies have now demonstrated the
association between benzodiazepine use and both greater
incidence
19 and duration
20 of delirium in medical ICU
patients, although the relationship of the development and
duration of delirium to sleep disruption was not ascer-
tained. Acute withdrawal from long-term sedation with
benzodiazepines and opiate narcotics results in profound
sleep disruption.
21 Interestingly, although the a2 agonists
can be used to treat symptoms of acute withdrawal from
psychoactive drugs, the effect they have on withdrawal-
induced sleep disturbances has not been reported.
Mechanisms and use of sedative-hypnotic agents
in the ICU
Benzodiazepines enhance fast inhibitory neurotransmission
by modulating the activity of GABAA receptors in
postsynaptic membranes. The GABAA receptor is a het-
eropentamer, and most GABAA receptors have a binding
site for benzodiazepines (formed by a and c2 subunits) in
addition to binding sites for the physiological neurotrans-
mitter GABA (formed by a and ß subunits).
22 Knock-in
studies perturbing the GABAA receptors in mice have
revealed that the a1 subunit in glutamatergic forebrain
neurons is necessary for changes in locomotion (sedation),
while the a2 subunit in hypothalamic nuclei is required for
the transduction of the hypnotic properties (and its attendant
EEG properties) of benzodiazepines.
23,24 Benzodiazepine
hypnotics depress slow-wave activity in NREM sleep, not
only during the night when subjects receive the drugs
but also during the subsequent night.
25 Neither sleep
homeostasis nor circadian rhythm is altered by acute ben-
zodiazepine administration. Recently, the dopaminergic
action of benzodiazepines has been revealed, which is
mediated through the a1 subunit containing GABAA recep-
tors in the reward centre (nucleus accumbens). The GABAA
receptors likely contribute to the addictive features of
benzodiazepines.
26
In a series of studies involving GABAergic agents, we
reported that, unlike NREM sleep, these hypnotic agents
did not alter noradrenergic activity in the locus ceruleus
(Fig. 1b).
27,28 Instead, these agents converged on the
NREM sleep pathway at the level of the hypothalamus.
28
Nonetheless, short-term administration of the GABAergic
agent, propofol, permits normal recovery after a period of
sleep deprivation, indicating similarities between propofol-
induced hypnosis and sleep.
29
Benzodiazepines also exert signiﬁcant memory-modu-
lating effects, though the extent to which they impair
explicit and implicit memory appears paradigm depen-
dent.
30 While some have suggested that both implicit and
explicit memory are impaired following administration of
midazolam,
31 only explicit memory is affected in
children.
32
We have shown that a2 agonists transduce their hypnotic
response after binding to the a2A receptor subtype
33 through
effects in the locus ceruleus (LC).
34,35 The noradrenergic
neurons become hyperpolarized and are less likely to
achieve an action potential due to signalling processes that
involve both pertussis toxin-sensitive G proteins
36 and
effector mechanisms, including inhibition of adenylyl
cyclase
34 and ligand-gated calcium channels as well as
activation of inwardly-rectifying potassium channels.
37
The relatively quiescent LC facilitates a series of
changes, including activation of the galanin/GABA-con-
taining neurons of the VLPO nucleus that terminate on and
inhibit aminergic neurons within the tuberomammillary
nucleus (Fig. 1c).
38 Thus, a2 agonists are associated with
similar changes in neuronal activity as is seen in NREM
sleep,
3,39 apart from the absence of an inhibitory effect on
the orexinergic neurons in the perifornical nucleus.
28 In a
functional magnetic resonance imaging (fMRI) study
comparing sedation with a2 agonists and benzodiazepines,
we showed that a thalamic nucleus receiving afferent input
from orexinergic neurons is activated during an arousal
stimulus in a2 agonist-sedated subjects but not in benzo-
diazepine-sedated subjects.
40 The preservation of orexin
Box
Delirium is deﬁned by the presence of disturbed consciousness (reduced clarity of awareness of the environment with reduced ability to focus, to
sustain, or to shift attention) and a change in cognition (such as memory deﬁcit, disorientation, or language disturbance) or the development of
a perceptual disturbance that is not better accounted for by a pre-existing, established or evolving dementia. The disturbance develops acutely
(usually hours to days) and tends to ﬂuctuate during the course of the day. Delirium may exhibit hyperactive or hypoactive features. Key risk
factors for delirium include age, co-morbidity, an acute inﬂammatory precipitant, sleep deprivation and sedative medication that targets
c-aminobutyric acid (GABA)A receptors.
Reference: American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: APA, 1994
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123signalling may account for the patient rousability noted
with dexmedetomidine sedation. In turn, this clinical effect
may be important in permitting weaning from mechanical
ventilation and patient examination.
Compatible with overlapping neural substrates, dex-
medetomidine induces a very similar EEG pattern in
human volunteers as that seen in stages 2-4 of NREM
sleep.
41 Children sedated with dexmedetomidine exhibited
an EEG pattern that was similar to that seen in stage 2
NREM sleep.
42 Dexmedetomidine and sleep also share
similarities in hypercarbic ventilator,
43 hormonal,
44 and
auditory evoked response.
45
Recently, Veselis et al. addressed the effects of dex-
medetomidineinaparticularmemoryparadigm (continuous
recognition task) and reported less memory perturbation (if
any) than was seen with GABAergic agents.
46 In animal
studies, acutely-administered dexmedetomidine was noted
to have variable effects on learning and memory depending
on the dose.
47 Recently reported rat studies showed that
dexmedetomidine interferred only with memory formation
if perception of sensory input was decreased during very
deep levels.
48
Relevant clinical investigations
Two randomized controlled trials (RCTs) investigated
whether dexmedetomidine could provide superior sedation
to benzodiazepine sedation. The Maximizing Efﬁcacy of
Targeted Sedation and Reducing Neurological Dysfunction
(MENDS) RCT compared dexmedetomidine and loraze-
pam sedation in 106 mechanically ventilated patients (three
patients were withdrawn).
17 Sedation with dexmedetomi-
dine resulted in more days thriving without delirium or
coma, a lower prevalence of coma, and more on-target
sedation than lorazepam administration.
17 The follow-up
Safety and Efﬁcacy of Dexmedetomidine Compared with
Midazolam (SEDCOM) trial randomized 375 patients to
dexmedetomidine or midazolam sedation.
18 Though no
difference in time at target sedation was observed, patients
sedated with dexmedetomidine had a reduced prevalence
of delirium with a reduced duration of mechanical
ventilation.
18
While we did not randomize patients according to
whether they were septic on admission to our MENDS
RCT,
17 we had decided a priori to perform a post-hoc
analysis of septic vs non-septic subgroups of patients who
received dexmedetomidine-based or lorazepam-based
sedation for up to ﬁve days.
49 More than half of the 103
patients included (63 patients; 31 dexmedetomidine, 32
lorazepam) were admitted with sepsis. Demographic and
severity data were balanced between the two cohorts.
Compared with septic patients who received lorazepam, the
septic patients who received dexmedetomidine had 3.2
more delirium/coma-free days and more ventilator-free
days on average (95% conﬁdence intervals for difference,
Fig. 2 Days free from complications associated with acute brain
failure in septic intensive care unit patients sedated with the a2
adrenoceptor agonist, dexmedetomidine, or the benzodiazepine,
lorazepam. Data are represented in a box and whisker plot reﬂecting
the median, lower, and upper quartiles and the lower and upper
extremes of days/patient. Reproduced with permission from Pandha-
ripande et al.
49
Fig. 3 Kaplan-Meier curve showing the probability of survival
according to sedation group during the ﬁrst 28 days following
admission to the intensive care unit for sepsis. Avoidance of
lorazepam sedation using dexmedetomidine decreased the probability
of dying within 28 days by 70%. Reproduced with permission from
Pandharipande et al.
49
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1231.1-4.9 and 0.3-11.1, respectively) (Fig. 2). The risk of
dying at 28 days was reduced by 70% (hazard ratio 0.3:
0.1-0.9) in dexmedetomidine patients with sepsis compared
with the lorazepam patients (Fig. 3). In addition to alter-
nate effects on innate immunity and physiological response
to the infection,
49,50 we speculate that the immune dys-
functional effects of sleep deprivation in the lorazepam
group may have contributed to the higher death rate from
infection. Our speculation is supported by data from the
SEDCOM trial in which the rate of infection was 50%
lower in the DEX group.
18
Functional MRI was performed in volunteers tested on
three separate occasions during which they received sal-
ine, dexmedetomidine, or midazolam.
40 Subjects were
infused to achieve a target concentration that produced
equivalent sedation, as assessed by electroencephalogra-
phy (bispectral index [BIS]) and observer rating (Observer
Assessment of Alertness/Sedation [OAA/S]). In a single
subject, sleep occurred during saline infusion while
undergoing fMRI. Subtraction scans were performed to
yield the difference in blood oxygen level-dependent
(BOLD) activity between natural sleep and the sedated
states provided by either dexmedetomidine or midazolam.
There were fewer voxels of BOLD activity seen in the
subtraction scan between dexmedetomidine-sedation and
natural sleep (Fig. 4a) than between midazolam-sedation
and natural sleep (Fig. 4b).
The changes in neuronal activity that benzodiazepines
induce are inconsistent with the deeper stages of NREM
sleep. Consequently, the restorative properties of natural
sleep are lacking in patients on prolonged benzodiazepine
infusions, resulting in acute brain and immune system
dysfunction that may complicate the recovery of critically
ill patients. The addictive properties of benzodiazepines
result in a rapid escalation in dose requirements. When
benzodiazepines are part of the sedative regimen, it is
difﬁcult to perform ‘‘interruption of sedation’’ standard of
nursing care because of the likelihood of the supervention
of withdrawal phenomena, including a hypernoradrenergic
state and anxiogenesis.
Conclusions
Sedative-hypnotic agents contribute to the development
of delirium in critically ill patients.
17-19 We hypothe-
size that a2 adrenoceptor agonists are beneﬁcial relative
to benzodiazepines due to subtle differences in their
Fig. 4 Sedation with a2 adrenoceptor agonist produces a more
‘‘natural sleep’’ response than sedation with benzodiazepine. Func-
tional magnetic resonance imaging (fMRI) was performed in
volunteers tested on three separate occasions, during which they
received saline, dexmedetomidine, or midazolam.
40 Subjects were
infused to achieve a target concentration that produced equivalent
sedation as assessed by electroencephalography (bispectral index,
BIS) and observer rating (Observer Assessment of Alertness/Seda-
tion, OAA/S). In a single subject, sleep occurred during saline
infusion while undergoing fMRI. Subtraction scans were performed
yielding the difference in blood oxygen level-dependent (BOLD)
activity between natural sleep and the sedated states provided by
either dexmedetomidine or midazolam. There were fewer voxels of
BOLD activity seen in the subtraction scan between dexmedetomi-
dine-sedation and natural sleep (a) than seen between midazolam-
sedation and natural sleep (b)
c
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123mechanisms of action. In particular, we suggest that
dexmedetomidinesedationmayprovideamorerestorative–
perhaps ‘‘natural sleep-like’’ - state than GABAergic seda-
tives, such as the benzodiazepines. Our proposition centres
on the discovery that a2 adrenoceptor agonists act on the
sleep pathway at the brainstem level, while GABAergic
agents act at the level of the hypothalamus. The dissimilar
actions produce different sedative proﬁles for the two clas-
ses of agents, and we suspect they contribute to the risk of
delirium in the intensive care unit through alternate effects
on the restorative nature of the sedation. This may also
explainwhyoutcomesfromsepsis
49andinfection
18arevery
different for a2 adrenoceptor agonists than they are for
GABAergic agents (though we suspect ongoing studies will
identify the importance of the immune actions of the two
drug classes). Furthermore, a2 adrenoceptor agonists may
provide a state from which patients are rousable, possibly
through preserved orexinergic signalling. Rousability is
important to facilitate weaning from mechanical ventilation
and neurological examination. Finally, in addition to pre-
venting the cognitive consequences of sleep deprivation, the
drugs alternately affect memory formation. We suggest that
the impairment of memory formation by GABAergic drugs
contributes to the acute confusion in delirium, while a2
adrenoceptor agonists produce little in the way of memory
impairment and thus reduce the burden of patient
disorientation.
Clinical studies continue to reveal the beneﬁts of
understanding the differences in sedative-hypnotic mech-
anisms, and as further mechanistic understanding can
drive advances in clinical medicine, we urge clinicians
and scientists alike to continue this fruitful path of dis-
covery to aid patient care at the bedside. The adoption
of ‘‘sedation holidays’’
51 and ‘‘spontaneous breathing
trials’’
52 have shown that sedation in our most vulnerable
patients is an important determinant of outcome. We
now have the opportunity to deﬁne the agents for best
sedating our patients, and we suggest that a2 adrenoceptor
agonists may offer particular advantages in the critically
ill.
17,18,49,50
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